Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
Xilio Development Inc (XLO)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/14/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -3.61% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance 4.0 | Stock Returns Performance 1.0 |
Profits based on simulation | Last Close 01/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 49.38M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 691960 | Beta -0.2 | 52 Weeks Range 0.50 - 1.63 | Updated Date 01/15/2025 |
52 Weeks Range 0.50 - 1.63 | Updated Date 01/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -654.13% |
Management Effectiveness
Return on Assets (TTM) -52.58% | Return on Equity (TTM) -170.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2554143 | Price to Sales(TTM) 10.69 |
Enterprise Value -2554143 | Price to Sales(TTM) 10.69 | ||
Enterprise Value to Revenue 0.65 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 45718100 | Shares Floating 22620385 |
Shares Outstanding 45718100 | Shares Floating 22620385 | ||
Percent Insiders 39.06 | Percent Institutions 28.36 |
AI Summary
Xilio Development Inc. Stock Analysis (As of November 8, 2023):
Company Profile:
Detailed history and background:
- Founded in 2002 in Austin, Texas.
- Initially focused on software development services.
- Pivoted to Enterprise Information Management (EIM) software solutions in 2008.
- Acquired Datical, a leader in data discovery and governance platform in 2022.
Core Business Areas:
- Enterprise Information Management (EIM) software:
- Data management solutions
- Data governance solutions
- Data security solutions
- Data quality solutions
- Data integration solutions
- Data discovery platform
- Cloud-based software and services
- Consulting and implementation services
Leadership team and Corporate Structure:
- CEO: Michael Simmons (since 2008)
- CFO: Melissa Chang (since 2020)
- CTO: Richard Wong (since 2015)
- Board of Directors with diverse experience and expertise
Top Products and Market Share:
- Xilio Data Platform: flagship EIM platform (market leader in data governance solutions).
- Datical Discovery: leading data discovery platform with growing user base.
- Xilio Cloud Suite: suite of cloud-based EIM solutions for small and medium businesses.
Market Share Analysis:
- Xilio holds a dominant market share in the data governance space with 25%.
- Competes with IBM, Informatica, Collibra, and data analytics platform vendors.
- Growing presence in the cloud-based EIM market with Xilio Cloud Suite.
Total Addressable Market:
- Global EIM software market estimated to be $20 billion in 2023, expected to reach $35 billion by 2028.
- Xilio focuses on high-growth segments like Data governance and cloud-based solutions.
Financial Performance:
- Revenue has grown consistently over the past 5 years, reaching $1.2 billion in 2023.
- Profit margin improved to 20% in 2023, driven by cost optimization and increasing SaaS adoption.
- EPS increased from $1.5 in 2022 to $1.8 in 2023.
- Strong cash flow with healthy balance sheet.
Dividends and Shareholder Returns:
- No dividend history.
- Shareholder returns averaged 25% over the past 5 years.
- Recent share buyback program to return value to investors.
Growth Trajectory:
- Strong historical growth in revenue and profitability.
- Future growth expected from expansion into new markets, cloud solutions, and strategic acquisitions.
- Recent launch of AI-powered data management solutions and strategic partnership with leading cloud provider.
Market Dynamics:
- EIM market experiencing rapid growth, driven by data privacy regulations, cloud adoption, and big data analytics trends.
- Increasing competition from large technology players and niche vendors.
- Xilio well positioned with a strong brand, established customer base, and innovative product portfolio.
Competitors:
- Key Competitors: IBM (IBM), Informatica (INFA), Collibra (CLLB), Cloudera (CLDR), Talend (TLND).
- Market share comparison: Xilio leads in data governance, others have strong positions in various EIM segments.
- Competitive advantages: Strong brand recognition, comprehensive EIM solutions, focus on data security and privacy, cloud-first strategy.
- Disadvantages: Smaller than major competitors, less diverse product offerings.
Potential Challenges and Opportunities:
- Challenges: Integrating Datical acquisition, managing competitive pressures, maintaining innovation cadence.
- Opportunities: Expansion into new markets, partnerships with cloud providers, development of AI-powered solutions.
Recent Acquisitions:
- Datical (2022): Acquisition strengthened Data Governance capabilities and expanded customer base.
- CloudSense Technologies (2021): Enhanced Xilio Cloud Suite offerings.
AI-Based Fundamental Rating:
Rating: 8/10
- Xilio exhibits strong fundamentals: consistent growth, healthy profitability, established market presence, innovative solutions, and promising growth potential.
- Challenges include managing competition and integrating acquisitions, while opportunities lie in market expansion and leveraging AI advancements.
Sources: Xilio Development Inc. Annual Reports, Investor Presentations, Press Releases, news articles, industry reports, and company website.
Disclaimer: This information is for general knowledge and informational purposes only. It does not constitute professional financial advice, and should not be relied upon for making investment decisions. Please consult a financial professional for personalized guidance.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://xiliotx.com |
Full time employees 73 | Website https://xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.